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Comparing current and emerging practice 
models for the extrapolation of survival data: 
a simulation study and case-study
Benjamin Kearns1*, Matt D. Stevenson1, Kostas Triantafyllopoulos2 and Andrea Manca3 
Abstract 
Background: Estimates of future survival can be a key evidence source when deciding if a medical treatment should 
be funded. Current practice is to use standard parametric models for generating extrapolations. Several emerging, 
more flexible, survival models are available which can provide improved within-sample fit. This study aimed to assess 
if these emerging practice models also provided improved extrapolations.
Methods: Both a simulation study and a case-study were used to assess the goodness of fit of five classes of survival 
model. These were: current practice models, Royston Parmar models (RPMs), Fractional polynomials (FPs), Generalised 
additive models (GAMs), and Dynamic survival models (DSMs). The simulation study used a mixture-Weibull model as 
the data-generating mechanism with varying lengths of follow-up and sample sizes. The case-study was long-term 
follow-up of a prostate cancer trial. For both studies, models were fit to an early data-cut of the data, and extrapola-
tions compared to the known long-term follow-up.
Results: The emerging practice models provided better within-sample fit than current practice models. For data-rich 
simulation scenarios (large sample sizes or long follow-up), the GAMs and DSMs provided improved extrapolations 
compared with current practice. Extrapolations from FPs were always very poor whilst those from RPMs were similar 
to current practice. With short follow-up all the models struggled to provide useful extrapolations. In the case-study 
all the models provided very similar estimates, but extrapolations were all poor as no model was able to capture a 
turning-point during the extrapolated period.
Conclusions: Good within-sample fit does not guarantee good extrapolation performance. Both GAMs and DSMs 
may be considered as candidate extrapolation models in addition to current practice. Further research into when 
these flexible models are most useful, and the role of external evidence to improve extrapolations is required.
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Background
Accurate extrapolations of future survival can be pivotal 
evidence sources for decision-makers when determining 
if a medical treatment should be funded. In England, the 
National Institute for Health and Care Excellence (NICE) 
– which provides national guidance on if treatments 
should be funded – requires that all relevant health bene-
fits of a treatment be quantified. This is to enable consist-
ent and fair decision making across diverse treatments. 
Hence if a treatment impacts on survival this should be 
extrapolated to provide estimates of lifetime survival 
benefit. Recent reviews of cancer treatments appraised by 
NICE found that between 2011 and 2017, every appraisal 
involved extrapolation [1]. On average, evidence on 
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treatment effectiveness was available for 2.9 years, and 
extrapolated to 25.2 years [2].
Current practice is to use standard parametric survival 
models (such as the exponential and Weibull) when ana-
lysing and extrapolating survival data [1]. There is a grow-
ing awareness that such models may not be sufficiently 
flexible to accurately capture the complex hazard patterns 
that may arise in practice [3, 4]. There are several more-
advanced survival models which may give improved fit to 
the observed data [5]. However, it is unclear if improved 
within-sample fit will lead to improved extrapolation 
performance, and there is dearth of comparative studies 
which include these flexible emerging practice models. 
The aim of this study was to compare both the within-
sample goodness of fit and the extrapolation perfor-
mance of current and emerging practice models. This 
was achieved using both a simulation study and a case-
study. Use of a case-study demonstrates the performance 
of survival models using real data, whilst use of a simula-
tion study avoids estimates of performance being driven 
by the quirks of a single dataset.
Methods
This section begins with an overview of the survival 
models used, followed by details of the simulation study 
and case-study.
Survival models
For brevity, the descriptions here focus on the qualitative 
properties of the models. Technical details may be found 
in the references provided. A key distinction between 
the models is if they are global, piecewise, or local. For 
global models, parameter estimates are the same at all 
time points (constant over time). For piecewise models, 
parameter estimates are constant over time within speci-
fied time intervals but allowed to vary across time inter-
vals. For local models, parameter estimates vary over 
time. Five classes of survival model were considered:
1. Current practice [6, 7]. Eight standard parametric 
global survival models were considered: exponential, 
Weibull, Gompertz, log-logistic, lognormal, gamma, 
generalised gamma, and generalised F. The first five 
models may be written as linear models; this assump-
tion of linearity is relaxed by the emerging practice 
models of the other four model classes.
2. Royston Parmar models (RPMs) [8, 9]. These extend 
linear models by the incorporation of piecewise cubic 
polynomials, which are restricted to have the same 
value at a set of `knots’, with the number of knots 
determining the complexity of the model. Up to five 
internal knots were considered, with two specifica-
tions which correspond to extensions of the Weibull 
and log-logistic models, respectively.
3. Fractional polynomials (FPs) [10, 11]. These are 
global models; one and two polynomial terms of 
the logarithm of time were considered, giving FP (1) 
and FP (2) models, respectively. Powers were taken 
from the set [− 2, − 1, − 0.5, 0, 0.5, 1, 2, 3], result-
ing in eight FP (1) and 36 FP (2) models. It is possible 
to choose between FP (1) and FP (2) models using a 
closed-test procedure [12], but for this study FP (1) 
and FP (2) models were kept separate. This is because 
FP (2) models are more complex than FP (1) models, 
and there was interest in seeing if extrapolation per-
formance varied by model complexity.
4. Generalised additive models (GAMs) [13, 14]. The 
models considered start with a Weibull, and add 
complexity via additional parameters, known as 
bases. For this study regression splines were used, 
with a maximum dimension of ten. The likelihood 
for these models includes a term that penalises for 
model complexity, which leads to shrinkage of model 
parameters. GAMs are global models.
5. Dynamic survival models (DSMs) [5, 15]. These are 
local models which introduce flexibility by allowing 
model parameters to evolve over time, as described 
by a time-series. Two models were considered. Both 
extend a linear Weibull model by allowing the trend 
parameter to follow a random walk. The first model 
(‘local trend’) extrapolated this trend indefinitely. 
The second model (‘damped trend’) successively 
decreased the extrapolated trend as the time hori-
zon increased so that eventually the trend became 
zero and extrapolations were constant. The degree of 
dampening was estimated from the data.
Simulation study
The reporting of the simulation study follows published 
guidance [16]. Components of the simulation study are 
reported based on their aims (provided in the introduc-
tion), data generating mechanisms, methods (models), esti-
mand, and performance measures.
Data generating mechanism
A two-component mixture-Weibull model was used; it 
may be interpreted as representing two sub-populations 
of patients with either a high hazard (short survival) or a 
low hazard (long survival) The survival and hazard func-
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respectively, where γ and Λ are the respective shape and 
scale parameters (indexed by component), and ρ is the 
mixing proportion. The values used are: γ1 = 1.8, Λ1 = 
0.02, γ2 = 1.4, Λ2 = 2.3, and ρ = 0.5. This was designed to 
reflect a ‘true’ hazard with two turning points (at approx-
imately 0.5 and 1.75 years), and a long-term increasing 
hazard (reflecting the impact of ageing).
Nine scenarios were simulated, with 200 datasets simu-
lated for each scenario. These scenarios corresponded to 
three different sample sizes (small = 100, medium = 300, 
large = 600), and three different lengths of follow-up 
(short =  2 years, medium =  3 years, long =  4 years). 
Hence all scenarios included both turning points in the 
hazard function but varied by how soon after the last 
turning point follow-up ended. The sample sizes were 
chosen to be representative of those typically seen in 
clinical practice at the point of reimbursement deci-
sion making. Details on these scenarios are provided in 
Table 1 and visualised in Fig. A1 in Additional file 1.
Methods
The five classes of survival model previously described 
were included. For current practice, the generalised F 
was not included due to a lack of convergence. Further, 
the main results do not include the Gompertz model due 
its very poor extrapolation performance. Results includ-
ing the Gompertz are provided in Additional file  1. For 
the two DSM specifications (local trend, damped trend), 
a constant level (intercept) as well as a time-varying local 
intercept was considered, resulting in four DSMs. For the 
first three model classes multiple specifications are pos-
sible. In practice, the choice between these specifications 
would be based on a combination of clinical considera-






















choice between model specifications was based solely on 
Akaike information criteria (AIC) for current practice, 
RPM, FP [1] and FP [2] models [18]. All analyses were 
performed in R, using a variety of packages [7, 19, 20]. 
Full details on the packages used and implementation 
and provided in Additional file 2.
Estimand and performance measures
The estimand was the mean of the natural logarithm of 
the time-varying hazard function λt. The primary perfor-
mance measure used was the mean (of the) squared error 
(MSE), with bias as a secondary performance measure. 
For MSE smaller values indicate better model perfor-
mance, for bias this is indicated by values closer to zero. 
Further details on the justification for these measures and 
their definition are provided in Additional file 1.
Case‑study
Patient-level data were obtained for the clinical trial COU-
AA-301 (NCT00638690) from the Yale University Open 
Data Access Project [21]. This trial compared abiraterone 
acetate (henceforth referred to as abiraterone) to placebo in 
people with castration-resistant prostate cancer previously 
treated with docetaxel-based chemotherapy. The available 
data was for 1183 people (abiraterone = 791, placebo = 392) 
with almost complete follow-up: median 36.2 months, by 
which time 984 (82.3%) people had died. An early cut of the 
data has been published, based on a median follow-up of 
12.8 months and 552 deaths (46.2%) [22]. The five classes 
of survival model were applied to the early cut of the data, 
with the more complete data used to evaluate the extrap-
olation performance. More details on the available data, 
including how the early cut was replicated, are provided 
in Additional file 1. For classes one to three, multiple mod-
els may be fit. The choice of model(s) to use for extrapo-
lations was based on a combination of the plausibility of 
Table 1 Details of the nine scenarios simulated
Scenario Follow‑up (survival %) Sample size
Short follow-up, small sample size 2 years (46.8%) 100
Short follow-up, medium sample size 300
Short follow-up, large sample size 600
Medium follow-up, small sample size 3 years (43.3%) 100
Medium follow-up, medium sample size 300
Medium follow-up, large sample size 600
Long follow-up, small sample size 4 years (39.2%) 100
Long follow-up, medium sample size 300
Long follow-up, large sample size 600
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extrapolations and the goodness of fit to the observed data, 




For each model, the visual patterns of within-sample fit 
and extrapolations were broadly similar across the nine 
scenarios considered. Increasing the sample size led to a 
reduction in the variation of extrapolations as expected 
but had little other effect. Results were more sensitive to 
changes in length of follow-up. For a sample size of 300 
and all three follow-ups and all nine models, Fig. 1 dem-
onstrates visual fit whilst Fig.  2 provides time- varying 
estimates of the MSE and bias (due to their very poor fit, 
FPs are excluded from Fig. 2). Plots for the remaining sce-
narios are provided in Additional file 1 (Figs. A2 to A5).
For the within-sample period, the current practice 
models provided a poor fit to the observed data for all the 
scenarios: the hazard was under-estimated for the first 
year and over-estimated for subsequent years, with nei-
ther turning-point in the hazard captured. The remaining 
models all provided visually improved within-sample fit, 
although they also typically had more variability in their 
estimates. With the shortest follow-up (2 years) none of 
the models identified the long-term increasing trend in 
the hazard function. With the longest follow-up (4 years) 
two dynamic models (local trend and damped trend 
models; both with a global level) along with the GAM 
identified the long-term increasing hazard; the remain-
ing models did not. For the three models that identified 
the long-term increasing hazard, the bias in the extrapo-
lations decreased with increasing sample-size; for the 
largest sample size they provided approximately unbi-
ased estimates. The extrapolation performance of the 
two DSMs with a local level also improved with increas-
ing sample size, but they consistently under-estimated 
the true hazard. In contrast, for the current practice 
models and RPMs, the bias was not reduced by increas-
ing sample size. Results for a follow-up of 3 years were 
similar to those for 4 years, but with more uncertainty in 
the extrapolations. This uncertainty led to some extreme 
departures from the true hazard values for the GAMs 
and DSMs. In contrast, use of standard models or RPMs 
led to extrapolations that were always biased, but there 
were never any extreme departures from the truth.
In general, GAMs required less data (sample size or fol-
low-up) than DSMs to identify the turning-point in the 
hazard, but GAMs also produced more variable extrapo-
lation estimates than the DSMs. This large variation is a 
particular concern as in each appraisal (or analysis) only 
a single extrapolation would be obtained and there is a 
danger that it would correspond to one of the very poor 
extrapolations. For the DSMs, dampening the trend led 
to less variable extrapolations and lower average MSE 
and bias than the corresponding local trend models. Both 
FP model classes provided extremely poor extrapolations 
which very quickly tended towards zero or very large 
numbers and lacked face validity. Despite generally hav-
ing the worst within-sample fit, current practice mod-
els often provided some of the best extrapolations with 
short-to-medium follow-up. However, as demonstrated 
in Fig. 1, the good extrapolation performance of the cur-
rent practice models is an artifact of their poor within-
sample fit, as the extrapolated (decreasing) hazards were 
by chance close to the true (increasing) hazards. Esti-
mates from individual current practice models, includ-
ing the Gompertz, are provided in Additional file 1. The 
GAMs and RPMs are both spline-based models but pro-
duced very different extrapolations. Further comparison 
of these models is provided in Additional file  1, which 
shows that GAMs were generally more complex than the 
RPMs.
Overall values of MSE and bias (averaged across the 
within- and out-of-sample time periods) are provided in 
Table  2. For each of the nine scenarios considered, the 
DSM with a damped trend and a local level provided the 
lowest MSE values. The next lowest MSE values were 
typically observed for the current practice and RPMs, 
despite these two model types predicting a long-term 
decrease in hazards for all nine scenarios. As the scenar-
ios became more data rich (increasing follow-up and/or 
sample size), the performance of the DSMs improved rel-
ative to the other models. For example, with a sample size 
of 600 and four-years follow-up, the four DSMs had the 
lowest MSE of all the models considered. The class of FPs 
give the worst extrapolations for every scenario. This may 
be due to their sensitivity to extreme values, combined 
with extrapolating polynomial trends [23]. Omitting the 
FPs, the largest MSE values were observed for the GAM 
in seven of the nine scenarios. The poor performance of 
the GAMs is primarily driven by the large variability in 
extrapolations, as it provided the least-biased estimates 
in four scenarios. For the remaining five scenarios a DSM 
provided the least-biased estimates (two each for the two 
DSMs with a damped trend, one for the local trend global 
level DSM).
Case‑study
Within-sample estimates and extrapolations from the 
models selected for extrapolations are provided in Fig. 3, 
which also includes general population hazard values as 
a reference. Information criteria for the standard models 
and RPMs are provided in Additional file  1 (Table  A4). 
The Weibull and gamma models had very similar AIC 
and BIC values and for both treatment groups were the 
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Fig. 1 Model estimates of the log-hazard (blue lines) and true values (black lines)
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Fig. 2  Mean squared error and bias values by time (within-sample and extrapolations)
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two best standard models. Hence both were considered 
for extrapolation. For the abiraterone group, the RPM 
corresponding to the Weibull had the lowest AIC and 
BIC; models with increasing complexity had decreasing 
within-sample fit. For the placebo group use of AIC and 
BIC led to contrary findings. The BIC supported the use 
of a Weibull, whilst more complex models had better AIC 
values. Visually the more complex models appeared to 
be over-fitting the data, suggesting that in this instance 
AIC may not be sufficiently penalising model complex-
ity. Since the best-fitting (and plausible) RPM was the 
Weibull for both groups and this was already chosen as 
a standard model, no RPMs were used for extrapolation. 
For both groups, the FP1 with the lowest AIC was the 
same model as a Weibull. This model provided very simi-
lar visual estimates (within-sample and extrapolations) to 
the best-fitting FP2 but had lower AIC. As such, the FP1 
model corresponding to the Weibull was chosen for both 
groups.
The fitted GAM provided visual estimates that were 
very similar to the RPM with the lowest AIC, suggest-
ing a Weibull for abiraterone and a function with six 
turning points in the hazard for the placebo group. 
These are used for extrapolation even though it is 
noted that the placebo GAM may be over-fitting the 
data (resulting in very large extrapolated hazards). 
For the abiraterone group, both DSMs provide similar 
estimates to the Weibull model up to about 9 months. 
After this time, the local trend model estimates higher 
hazards than the Weibull and the damped trend model 
estimates lower hazards. Similar extrapolations were 
observed for the placebo group, with the damped trend 
providing the lowest extrapolated hazards of all mod-
els considered and the local trend the second highest 
(below the GAM).
A visual comparison of the model-estimates to the 
longer-term data is provided in Fig. 4, which also include 
a smooth non-parametric estimate (black-dashed line). 
For both treatment groups, the trend observed in the 
early data cut does not persist in the long-term. For the 
placebo group, the short-term increase in the hazard 
during the period of the interim data is followed by an 
almost immediate decrease. As such, none of the models 
provide good extrapolations. For the abiraterone group, 
the hazard continues increasing to about 2.5 years albeit 
at a lower rate than was observed in the early cut. The 
damped trend model provides adequate extrapolations 
up to about 2.5 years. After this time, the observed haz-
ards decrease, and none of the models provide a good 
description. Extrapolations beyond 3 years were not 
Table 2 Goodness of fit over the entire time horizon
FU Follow-up
Overall mean Sample size: 100 Sample size: 300 Sample size: 600
squared error FU: 2 years FU: 3 years FU: 4 years FU: 2 years FU: 3 years FU: 4 years FU: 2 years FU: 3 years FU: 4 years
Damped trend, local level 0.51 0.34 0.42 0.23 0.38 0.29 0.26 0.41 0.27
Current practice 1.01 1.19 1.26 0.94 1.15 1.19 0.90 1.12 1.15
Royston-Parmar model 1.98 2.38 1.87 2.21 2.38 1.50 2.25 2.36 1.40
Damped trend, global level 3.75 4.98 2.36 7.88 2.29 0.52 8.07 1.41 0.35
Local trend, local level 3.33 4.41 2.96 6.86 4.13 1.26 9.18 3.39 0.71
Local trend, global level 6.03 7.12 4.27 15.61 6.67 1.36 18.04 4.65 0.57
Generalised additive model 32.89 18.16 6.85 18.49 6.59 2.12 20.27 4.09 1.53
Fractional polynomial: order 1 312.40 103.82 22.49 326.43 41.25 8.61 331.78 35.71 9.14
Fractional polynomial: order 2 531.90 258.30 147.35 205.23 55.05 85.21 121.62 24.07 65.57
Overall bias
 Damped trend, local level 0.38 −0.03 − 0.19 − 0.12 − 0.35 − 0.40 − 0.30 −0.30 − 0.31
 Current practice −0.36 − 0.37 − 0.35 − 0.55 −0.55 − 0.54 −0.60 − 0.58 −0.56
 Royston-Parmar model −0.92 −1.07 − 1.10 − 1.07 − 1.10 − 1.11 −0.88 − 0.79 −0.77
 Damped trend, global level −0.35 − 1.83 − 1.80 − 1.17 −0.78 − 0.56 −0.76 − 0.18 −0.14
 Local trend, local level −0.93 − 1.80 −2.14 − 1.32 −1.36 − 1.23 −1.06 − 0.64 − 0.48
 Local trend, global level − 1.36 − 2.85 −3.13 −1.73 − 1.72 −1.30 − 1.31 − 0.45 − 0.11
 Generalised additive model −1.55 −2.18 − 1.99 − 0.06 − 0.09 0.05 0.15 0.31 0.23
 Fractional polynomial: 
order 1
−10.52 −11.87 − 12.24 −5.36 −4.10 − 3.91 −2.37 −1.75 − 1.83
 Fractional polynomial: 
order 2
−5.45 −8.03 −6.72 1.45 − 0.79 −1.84 4.05 3.53 3.08
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Fig. 3  Within-sample fit and extrapolations from candidate extrapolation models
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considered due to the small sample sizes (at 3 years the 
number of patients remaining in the study was 62 and 23 
for the abiraterone and placebo arms, respectively, whilst 
at 3.5 years the numbers were 24 and 3, respectively).
Discussion
The within-sample fit and extrapolation performance of 
several survival models was evaluated in nine simulated 
scenarios covering different lengths of follow up and dif-
ferent sample sizes. A single data-generating mechanism 
was used, with two turning points in the hazard function. 
Only the global-level DSMs and GAMs were able to cor-
rectly extrapolate an increasing hazard function, but only 
in the more data-rich scenarios, and extrapolations were 
highly variable.
Current practice models provided the worst within-
sample estimates of all the models considered in the 
simulation study. The DSMs and emerging practice mod-
els were able to provide improved within-sample fit due 
to their increased flexibility. However, this extra flex-
ibility sometimes resulted in overfitting and extrapolat-
ing short term trends in the data that were not present 
in the longer term. A stark example of this was observed 
for the two FP model classes, for which extrapolations 
tended sharply towards implausibly small or large values. 
The danger of the more flexible models overfitting was in 
general reduced with increased sample size or follow-up, 
which led to improved extrapolation performance. A cor-
responding improvement in extrapolation performance 
for the more data-rich scenarios was not observed for 
current practice models.
A strength of the simulation study is the large number 
of survival models considered. For each scenario DSMs, 
current practice, spline-based models, and fractional 
polynomials were all evaluated. When including differ-
ent model specifications, collectively 62 different models 
were fit for each scenario, with nine models retained for 
estimating extrapolation performance. The use of model 
selection also showed that within-sample goodness of fit 
plays a very limited role in identifying models that pro-
vide accurate extrapolations. For example, the current 
practice model with the best within-sample fit typically 
provided the worst extrapolations. A further strength 
of the study is the novel use of time-varying estimands 
instead of a single summary measure of accuracy such as 
the estimate of lifetime mean survival, which is affected 
Fig. 4  Comparisons of extrapolations against longer follow-up (dashed-lines)
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by both within and out-of sample fit (an accurate esti-
mate may occur if short-term over-estimates of hazard 
and long-term under-estimates cancel out, or vice-versa).
There are limitations to the simulation study. Only a sin-
gle data generating mechanism (a mixture Weibull) was 
considered, with only one set of parameters. The within-
sample fit and extrapolation performance of the candidate 
models in other settings is currently unknown and would 
be a fruitful area for future research. The existing data gen-
erating mechanism included two turning points, so in this 
sense favoured the more flexible models. However, survival 
data are inherently complex with a multitude of potential 
competing effects, such as ageing, frailty, treatment ben-
efits, and adverse events. Collectively these are likely to 
cause complex shapes in the hazard function. Cure models 
may also be used for survival data with a turning-point [24]. 
They were not used here as the simulation study did not 
involve a cured fraction nor was there any indication that 
the case-study included one. Future research could explore 
the performance of cure models under misspecification.
In the case-study, for both treatment groups the hazards 
observed in the early data cut were increasing and use of 
current practice models favoured either the Weibull or 
gamma. These both provided monotonically increasing 
extrapolated hazards. Similar extrapolations were obtained 
from the more flexible FPs, RPMs and GAMs, along with 
the local trend model. In contrast, the damped trend 
model provided extrapolations that increased at a much 
lower rate for both groups. For both treatment groups the 
true long-term hazards eventually decreased. As none of 
the considered models were able to extrapolate a turn-
ing point, their predictions were generally all poor. The 
damped trend model assumes that the hazard function will 
eventually change from increasing to constant; this is clos-
est to what occurred in the full dataset. However, as this 
is a single case-study, the generalisability of this finding 
to other scenarios is unclear. This case-study emphasises 
that any extrapolations are only as good as the dataset that 
is used. If the unobserved future contains turning points, 
then any extrapolation model would do poorly unless it 
incorporates external data to identify the turning points.
The simulation study was relatively simple, compris-
ing two monotonic (Weibull) hazard functions. Yet pro-
ducing accurate extrapolations was challenging, even 
with a follow-up of 3 years. The dataset and results of 
this manuscript will provide useful test-cases and bench-
marks for future research to see if it is possible to provide 
improved extrapolations. Collectively, the simulation study 
and case-study suggest several areas for future research. 
Future studies could seek to identify if there are certain 
situations when one or more of the model classes out-per-
forms the other models, and so may be used as the default 
approach. The current results suggest that whilst use of a 
damped-trend DSM may be beneficial, there is a danger 
that it will provide worse extrapolations than current prac-
tice models, especially in data-poor scenarios. This moti-
vates consideration of a variety of different models, with 
model choice made on a case-by-case basis. This choice 
would consider the specifics of the extrapolation prob-
lem, such as the plausibility of extrapolations, the rich-
ness of the available data, and the qualitative differences in 
extrapolations arising from different models. The results 
currently suggest that simpler models may be appropri-
ate in data-poor settings, although there is a danger that 
no extrapolations will be useful in these situations. Further 
research is required to understand the conditions under 
which evidence are rich enough to justify a more complex 
model. As an alternative to model selection, model averag-
ing could be performed [25]. The case-study demonstrated 
that extrapolations were poor when the available follow-up 
did not include all the turning-points in the hazard func-
tion. The simulation study showed that even if all the turn-
ing points are included extrapolations may still be poor. 
This illustrates the potential importance of incorporating 
external evidence to improve extrapolations [26]. Nei-
ther the case-study nor the simulation study explored the 
impact on extrapolations of including covariates effects. In 
general incorporating additional information is expected 
to improve within-sample fit, but is unlikely to alter the 
conclusions of this manuscript.
The simulation study demonstrated that in  situations 
when survival outcomes may arise from distinct patient 
populations, current practice models are unlikely to pro-
vide accurate estimates of the observed data or realistic 
extrapolations. Of the emerging practice models consid-
ered, DSMs and GAMs were the only ones able to capture 
the long-term behaviour of the hazard function. However, 
extrapolations from these more flexible models were more 
variable than extrapolations from current practice models 
and had the potential to be less accurate. In the case-study 
neither the current nor emerging practice models were able 
to provide accurate extrapolations. To conclude, emerging 
practice models may be currently viewed as another option 
in the toolkit of methods for the analysis and extrapolation 
of survival data. More experience of these models when 
used with different datasets is required to provide more 
specific guidance about their role, including the situations 
when they are likely to be the most useful.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12874- 021- 01460-1.
Additional file 1. 
Additional file 2. 
Page 11 of 11Kearns et al. BMC Medical Research Methodology          (2021) 21:263  
Acknowledgements
The below acknowledgement relates to the data used in the case-study:
This study, carried out under YODA Project 2018-2686, used data obtained 
from the Yale University Open Data Access Project, which has an agreement 
with JANSSEN RESEARCH & DEVELOPMENT, L.L.C.. The interpretation and 
reporting of research using this data are solely the responsibility of the authors 
and does not necessarily represent the official views of the Yale University 
Open Data Access Project or JANSSEN RESEARCH & DEVELOPMENT, L.L.C..
Authors’ contributions
BK designed and interpreted the analyses and drafted the manuscript. MS, KT, and 
AM contributed to the design and interpretation of the analyses, and substantively 
revised the manuscript. The authors read and approved the final manuscript.
Funding
BK was funded by the NIHR Doctoral Research Fellowship (DRF-2016-09-119) 
“Good Practice Guidance for the Prediction of Future Outcomes in Health 
Technology Assessment.” BK was supported in the preparation of this work by 
the HEOM Theme of the NIHR CLAHRC Yorkshire and Humber (www. clahrc- yh. 
nihr. ac. uk). The views expressed are those of the authors and not necessarily 
those of the National Health Service, the National Institute for Health Research, 
or the Department of Health and Social Care. Publication of study results was 
not contingent on the sponsor’s approval or censorship of the manuscript. 
There is no further funding to declare.
Availability of data and materials
Code is provided to replicate the generation and analysis of the simulation 
study (Additional File 2). Data used for the case-study may be obtained upon 
request from the Yale University Open Data Access Project (https:// yoda. yale. 
edu/ how- reque st- data).
Declarations
Ethics approval and consent to participate
This manuscript includes a secondary analysis of data (obtained in the clinical 
trial NCT00638690. The original trial was carried out in accordance with the 
Declaration of Helsinki and the Good Clinical Practice guidelines of the.
International Conference on Harmonization and was approved by relevant 
review boards, with all patients providing written informed consent. See 
DOI: https:// doi. org/ 10. 1056/ NEJMo a1014 618 for more information. Permis-
sion to use the data reported in the secondary analysis of this manuscript 
was obtained from the Yale University Open Data Access Project, de-
identified, and subject to a data use agreement. The clinical trial informed 





All the authors have seen and given their approval for the submitted version 
of the manuscript. The authors have no conflicts of interest to disclose.
Author details
1 School of Health and Related Research. Regent Court (ScHARR), The Univer-
sity of Sheffield, 30 Regent Street, Sheffield S1 4DA, UK. 2 School of Mathemat-
ics and Statistics, The University of Sheffield, 30 Regent Street, Sheffield S1 
4DA, UK. 3 Centre for Health Economics, The University of York, York, UK. 
Received: 18 June 2021   Accepted: 8 November 2021
References
 1. Bell Gorrod H, Kearns B, Thokala P, Labeit A, Stevens J, Latimer N, et al. 
Plausible and consistent tails: a review of survival extrapolation methods 
used in technology appraisals of cancer treatments medical decision 
making : an international journal of the Society for Medical Decision Mak-
ing. 2019.
 2. Gallacher D, Auguste P, Connock M. How do Pharmaceutical companies 
model survival of Cancer patients? A review of NICE single technology 
appraisals in 2017. Int J Technol Assess Health Care. 2019;35(2):160–7.
 3. Gibson E, Koblbauer I, Begum N, Dranitsaris G, Liew D, McEwan P, et al. 
Modelling the survival outcomes of Immuno-oncology drugs in eco-
nomic evaluations: a systematic approach to data analysis and extrapola-
tion. PharmacoEconomics. 2017:1–14.
 4. Crowther MJ, Lambert PC. A general framework for parametric survival 
analysis. Stat Med. 2014;33(30):5280–97.
 5. Kearns B, Stevenson M, Triantafyllopoulos K, Manca A. Generalized linear 
models for flexible parametric modeling of the Hazard function. Med 
Decis Mak. 2019;39(7):12.
 6. Collett D. Modelling survival data in medical research (third edition): CRC 
press; 2015.
 7. Jackson CH. Flexsurv: a platform for parametric survival modeling in R. J 
Stat Softw. 2016;70(8):1–33.
 8. Lambert PC, Royston P. Further development of flexible parametric mod-
els for survival analysis. Stata J. 2009;9(2):265.
 9. Royston P, Parmar MK. Flexible parametric proportional-hazards and 
proportional-odds models for censored survival data, with application 
to prognostic modelling and estimation of treatment effects. Stat Med. 
2002;21(15):2175–97.
 10. Binder H, Sauerbrei W, Royston P. Comparison between splines and 
fractional polynomials for multivariable model building with continu-
ous covariates: a simulation study with continuous response. Stat Med. 
2013;32(13):2262–77.
 11. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic 
approach to regression anaylsis based on fractional polynomials for 
modelling continuous variables: John Wiley and Sons; 2008.
 12. Kearns B, Ara R, Young T, Relton C. Association between body mass index 
and health-related quality of life, and the impact of self-reported long-
term conditions–cross-sectional study from the South Yorkshire cohort 
dataset. BMC Public Health. 2013;13(1):1009.
 13. Wood SN. Stable and efficient multiple smoothing parameter estimation 
for generalized additive models. J Am Stat Assoc. 2004;99(467):673–86.
 14. Wood SN. Generalized additive models: an introduction with R (second 
edition): CRC press; 2017.
 15. Hemming K, Shaw J. A class of parametric dynamic survival models. 
Lifetime Data Anal. 2005;11(1):81–98.
 16. Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate 
statistical methods. Stat Med. 2019;48(11):2074–102.
 17. Rutherford MJ, Crowther MJ, Lambert PC. The use of restricted cubic 
splines to approximate complex hazard functions in the analysis of time-
to-event data: a simulation study. J Stat Comput Simul. 2015;85(4):777–93.
 18. Burnham KP, Anderson DR. Multimodel inference: understanding AIC and 
BIC in model selection. Sociol Methods Res. 2004;33(2):261–304.
 19. Team SD. RStan: the R interface to Stan; 2018.
 20. Wood SN, Pya N, Säfken B. Smoothing parameter and model selection for 
general smooth models. J Am Stat Assoc. 2016;111(516):1548–63.
 21. Ross JS, Waldstreicher J, Bamford S, Berlin JA, Childers K, Desai NR, et al. 
Overview and experience of the YODA project with clinical trial data shar-
ing after 5 years. Scientific data. 2018;5(1):1–14.
 22. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abira-
terone and increased survival in metastatic prostate cancer. N Engl J Med. 
2011;364(21):1995–2005.
 23. Magee L. Nonlocal behavior in polynomial regressions. Am Stat. 
1998;52(1):20–2.
 24. Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. The Extrapolation 
Performance of Survival Models for Data With a Cure Fraction: A Simula-
tion Study. Value in Health. 2021;In press.
 25. Thamrin SA, McGree JM, Mengersen KL. Modelling survival data to 
account for model uncertainty: a single model or model averaging? 
SpringerPlus. 2013;2(1):1–13.
 26. Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A, et al. Extrapo-
lating survival from randomized trials using external data: a review of 
methods. Med Decis Mak. 2017;37(4):377–90.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
